DEKKERS MARIJN E 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Jun 20, 2023
Insider Transaction Report
Form 4
DEKKERS MARIJN E
Director
Transactions
- Sale
Common Stock
2023-06-15$34.43/sh−200,000$6,886,000→ 402,326 total(indirect: See footnote)
Holdings
- 31,822
Common Stock
Footnotes (2)
- [F1]Represents shares held by Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"). The Reporting Person, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F2]Includes 3,282 Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan on June 7, 2023. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date.